A very large proportion of extremely preterm infants receive treatments for hypotension. There are, however, marked variations in indications for treatment, and in the interventions used, between neonatal intensive care units and between neonatologists.
Introduction
The diagnosis of hypotension and its subsequent management are controversial areas in the care of the very low birth weight (VLBW, <1500 g) newborn infant. 1 The frequency of hypotension varies between neonatal intensive care units (NICUs) even when the same diagnostic criteria are applied. 2 The frequency of intervention also varies dramatically, 3, 4 from 29 to 98% among infants less than 28 weeks gestation. 5 Several studies have attempted to determine normal ranges of blood pressure (BP) in the newborn infant. [6] [7] [8] [9] [10] [11] [12] [13] However, the ranges presented vary considerably for a number of reasons including: retrospective data collection, small numbers of patients included, combined invasive and noninvasive measurements, inclusion of small for dates and appropriate for gestational age infants, collection of only a few data points and averaging data points over wide time ranges. In some instances, a single absolute mean BP value has been chosen and applied over a wide range of gestational and post-natal ages 14 which ignores the increase in usual BP with increasing gestational age, and the usual spontaneous increase in BP over the first few post-natal days. The Joint Working Group of the British Association of Perinatal Medicine has recommended that the mean arterial BP in mm Hg should be maintained at or greater than the gestational age in weeks. 15 There appear to be no published data to support this recommendation; however, it is one of the commonest criteria used to define hypotension.
Definitions of what is normal, in an inherently abnormal population, the very preterm infant, require a different conceptual framework. Should definitions of normal ranges be statistically defined, and based on the entire population or only on relatively healthy infants with an eventual good outcome? It would be more useful to know what is a 'safe' BP, rather than a statistically defined 'normal' range. To determine a 'safe' BP, adequate prospective studies reporting the positive predictive value or likelihood ratio for adverse outcome depending on whether the BP was below the threshold would be necessary. Even more useful would be a 'treatment' BP, that is, a threshold below which intervention had been proven to improve clinically important outcomes; this requires prospective randomized trials powered for clinical outcomes.
The principle concern regarding hypotension is an assumed detrimental effect on end organ perfusion. However, perfusion is dependent both on pressure gradient and on vascular resistance and is only directly correlated with BP if resistance and outflow pressure are constant. 16 The critical clinical questions, therefore, are whether low BP (however defined) results in an adverse clinical outcome, including adverse short-term outcomes (increased incidence of brain injury or intestinal injury in particular) and adverse long-term neurodevelopmental outcome and, if so, does intervention to treat hypotension result in improved outcomes?
The objectives of this review were to determine if there exists sufficient evidence to determine which preterm infants may benefit from interventions to elevate BP, and which interventions improve clinically important outcomes. These objectives created three questions:
(1) Is there a defined BP threshold, or other clinical characteristics in preterm infants, which accurately identify those at risk for a poor outcome? (2) Is there evidence that infants with hypotension (either as defined in #1 or arbitrarily) may have improved clinical outcomes if they receive intervention? (3) Is there evidence regarding which interventions are most effective?
Methods
We performed systematic reviews of the literature in order to address the three objectives above.
To address objective #1 we sought prospective inception cohort studies of very preterm or VLBW infants, with regular assessment of BP using reliable methodology, and evaluation of ultrasound findings by investigators unaware of the BP findings. The infants should have received no therapy for their BP. The outcome variables required were death, severe intraventricular hemorrhage (IVH), either intraventricular with ventricular dilatation or intraparenchymal hemorrhage, or other parenchymal cerebral injury such as cystic periventricular leukomalacia (PVL). We were also interested in studies that examined long-term outcomes, such as Bayley scores of infant development, IQ testing or other indicators of long-term outcome.
In November 2006, we performed a search using PubMed and the terms 'BP or hypotension' 'premature or preterm' and 'IVH or PVL or development'. The search was run both with and without limits (clinical studies, humans and newborn infants, using the PubMed 'limits' facility) and using both MESH terms and unrestricted searches. The articles found were screened to determine potential applicability, and any study which appeared from this initial screen to be an evaluation of risk factors for IVH or PVL, or an analysis of normal BPs in preterm infants, was examined in its entirety. We also searched personal article files and the reference lists of recent review articles. This process produced 16 article,s which appeared likely to provide information about the relationship between BP and ultrasound brain abnormalities in the neonatal period. 8, 13, 14, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] These articles are described in Table 1 .
Blood pressure thresholds
After examining the abstracted information in Table 1 , it will be clear that there are no studies that completely satisfied the a priori requirements stated above. One particular limitation that should be emphasized is the importance of using gestational age and post-natal age appropriate normal values. If for example a single threshold for hypotension of 30 mm Hg is used to define hypotension, then the more immature infants (who are at greater risk of severe IVH) will be more likely to be deemed hypotensive, this will artifactually appear to show that hypotension is related to IVH. Either a statistical correction for gestational age or birth weight, or better, the use of normal values appropriate for the individual baby is required to prevent this artifact. The four studies that appeared to satisfy the largest proportion of our criteria are described below in more detail. They each had repeated measurements of BP and reliable descriptions of cranial ultrasound findings. Miall-Allen 14 was the only study to use masked evaluation of the head ultrasound findings, they also had continuous invasive BP monitoring. They found an excess of IVH/PVL in hypotensive preterm infants, however the threshold value was a single value of a mean BP less than 30 mm Hg, and the sample size was only 33 infants of 26 to 0 weeks gestation, 9 of whom developed either a major IVH or PVL. Bada et al. 31 found that infants in whom grade 2 to 4 IVH developed had lower BP values for their post-natal age than matched control infants without IVH. However, the normal values were only derived from 16 infants less than 1 kg and it was not possible to calculate birth weight or gestation-specific BP thresholds from the presented data. Watkins 8 reported a retrospective study which appears to have included the entire cohort of VLBW admitted to the NICU. Having taken post-natal age and birth weight into account, they identified an association between prolonged duration of a BP below the 10th percentile for birth weight and post-natal age, and the frequency of IVH. However, there was no correction for other risk factors. Cunningham 27 in a retrospective cohort study, reported that IVH was associated with a 'low BP' the day before IVH, but no details are given regarding the schedules of echoencephalography or what was meant by low BP for this result. Furthermore, any infant with a mean arterial BP less than the gestational age in weeks received intervention with a colloid bolus followed by inotrope infusion, and other infants with BP above this threshold were treated if perfusion was poor. They excluded periods when infants received >10 ml/kg of colloid, which occurred in 83% of the infants under 750 g. They found no association between the development of IVH and the duration of time when the mean BP was less than gestational age. All of these previous studies were confounded by the fact that pressor agents were used in at least some of the hypotensive infants.
Data from the Canadian Neonatal Network 32 found a slightly increased risk of IVH in patients less than 28 weeks gestation whose lowest recorded BP on day 1 was below their gestational age in weeks, and also when the lowest recorded BP was below the normal values produced by Watkins et al., 8 but the associations disappeared after correcting for the use of pressor agents. Martens et al. 30 examined the influence of hypotension on abnormalities at term using the Prechtl examination, and defined hypotension as a mean BP<30 mm Hg on at least two occasions. They found an association between hypotension defined in this way and an abnormal examination.
The study of the effects of hypotension on long-term outcomes by Goldstein et al. 23 included infants less than 1500 g and defined hypotension as a systolic BP less than 35 mm Hg for infants with a birth weight <750 g and <40 mm Hg for 750 to 1500 g, regardless of post-natal age. They included BP measured both by cuff and indwelling arterial lines. They found a correlation between the duration of BP less than this threshold and lower psychomotor developmental index on the Bayley scales of infant development at 2 years.
Therapeutic interventions
To address objective #2 we searched the literature for studies comparing an active intervention either to no intervention or to placebo in hypotensive preterm infants. We accepted systematic reviews of randomized controlled trials, individual randomized controlled trials or quasi-randomized trials, which included hypotensive preterm infants, and reported clinically important outcomes (survival, brain or lung injury, long-term neurodevelopmental outcome). In November 2006, we performed a search using PubMed for the terms 'blood pressure or hypotension', 'premature or preterm' and 'volume or bolus or fluid or dopamine or dobutamine or epinephrine or glucocorticoid or cardiotonic agents-therapeutic use'. The search was limited to clinical studies in humans, and newborn infants, using the PubMed 'limits' facility. The searches allowed us to find studies investigating volume expansion, inotropic support and steroid administration.
In order to address objective #3 we searched for studies comparing two interventions to each other, the same search terms were employed and randomized controlled trials in hypotensive preterm infants were enrolled into parallel groups comparing two interventions. The same clinically important outcomes were sought.
Volume expansion
Comparisons with no intervention A Cochrane review 33 addressed the role of early volume expansion for prevention of morbidity and mortality in very preterm infants, our search revealed no publications that were not included in the Cochrane review. Various fluids have been administered including saline, albumin, plasma substitutes or blood. Five studies compared volume to no treatment in patients without cardiovascular compromise. There are no controlled trials comparing the use of fluid boluses to no fluid boluses in preterm infants with cardiovascular compromise, specifically hypotension. Therefore, there is no evidence to support the use of volume for treatment of hypotension in the premature newborn with hypotension.
Comparisons of two fluids
Comparisons of two different fluids have been performed in four trials. One study 34 compared fresh frozen plasma to albumin in patients with a systolic BP less than 40 mm Hg and found no difference in the increase in systolic BP 1 and 4 h post-infusion, and no clinically important outcomes were presented. No long-term data were presented. Three other trials have compared a colloid to a crystalloid and in all three cases, 5% albumin was compared to normal saline. One found 35 no difference in treatment failure or P/IVH or mortality. Another found that the BP increase was greater with colloid than crystalloid, but no clinical outcomes were reported. 36 The third also found no difference between fluids, 37 but no data on morbidity and mortality were presented.
Catecholamine use
We identified 18 controlled trials and 5 systematic reviews of inotrope/vasopressor use in the preterm infant, all of which address catecholamines.
Comparison with no treatment
There are four trials of dopamine use in the preterm with untreated controls, in none of these were clinically important outcomes reported and in none was hypotension required as an entry criterion. Cuevas 38 investigated routine use of dopamine in ventilated preterm infants and showed no significant effect on renal function. A systematic review 39 concluded that there is no evidence that low-dose dopamine has favorable effects on renal function, including urine flow, and creatinine clearance or on beneficial clinical outcomes. Three studies, investigating the effects of dopamine on renal dysfunction due to indomethacin therapy, were the subject of a Cochrane Systematic Review, 40 which concluded that there was no evidence of renal protection from dopamine during indomethacin therapy.
Comparisons of two inotropes
There are five studies that compare the effects of dopamine versus dobutamine in systemic hypotension. These are the subject of a Cochrane review 41 which concludes that dopamine is more likely to increase BP than dobutamine, but that there is no evidence of a differential effect on clinical outcomes. Three had data on mortality, three had data on PVL and two had data on severe IVH, none of which were significantly different between the two drugs. A further study 42 compared dopamine versus dobutamine in cases of low systemic flow during the first 12 h of life. A total of 42 patients initially received a 10 ml/kg normal saline bolus followed by one inotrope or the other. Dopamine resulted in a significant increase in BP, whereas dobutamine resulted in a significantly greater increase in superior vena cava (SVC) flow. There was no difference in mortality or other clinically important outcomes.
In four studies comparing dopamine to other inotropes, blood flows have been measured. [42] [43] [44] [45] One of these studies is included in the previously mentioned Cochrane review addressing dopamine versus dobutamine for hypotension. All these four showed that when dopamine was given in sufficient doses to increase BP, there was a decrease in left ventricular output, in the region of about 20% in each study. In contrast, dobutamine increased left ventricular output in two of these studies 43, 37 and superior vena cava flow in the other 42 and epinephrine increased left and right ventricular output. 45 Only the study by Roze et al. 43 has reported clinically important outcomes, which were not different between groups.
There is very little evidence concerning the use of epinephrine for hypotension in the premature infant. Gaissmaier 46 in a randomized trial evaluated the use of dexamethasone for treatment of hypotension in a cohort concurrently starting an epinephrine infusion. They documented an increase in mean BP of at least 13 mm Hg over the first 12 h in the placebo group compared with a mean of 15 mm Hg in the treatment group. Heckmann et al. 47 published a retrospective review of epinephrine use in 34 preterm babies. They documented an increase in BP and heart rate with no change in urine output in VLBW infants already on a dopamine infusion. Two randomized studies compare epinephrine with dopamine in hypotensive preterm infants. The first by Philipos et al. 45 was a randomized double-blinded study comparing epinephrine versus dopamine and measured the effects of both agents on BP, left and right ventricular output and stroke volume. Both dopamine and epinephrine caused a significant increase in mean BP and heart rate, but dopamine resulted in a 10% decrease in left ventricular output, while epinephrine resulted in a 10% increase in left ventricular output. The second study by Pellicer 48 measured the effects of epinephrine versus dopamine on cerebral oxygenation and appeared to show an improvement in cerebral perfusion, which was identical in the two groups. Clinical outcomes of these infants were reported separately and there was no difference in short-term clinical effects. 49 No data on long-term outcome are provided in any of these studies.
In summary, there are a number of small studies addressing the short-term effects on physiologic variables of various different catecholamines. Dopamine appears to reliably increase BP, but this is usually accompanied by, 50 and is sometimes entirely due to, increasing vascular resistance. 51 Renal function and urine output are not reliably increased by dopamine. Dobutamine does not reliably increase BP but usually will increase left ventricular output. Epinephrine (very limited data) increases BP and left ventricular output. However, there is no clear evidence that clinically important outcomes are improved by the use of any of these catecholamine agents. These need to be addressed, especially in light of recent findings of the Canadian Neonatal Network, 32 suggesting a worse outcome in hypotensive patients who received inotropic support compared to hypotensive patients who were untreated.
Glucocorticoids
Steroids compared to no therapy Our searches found six prospective randomized trials addressing corticosteroid use for both prevention 52, 53 and treatment 39,46-48 of hypotension 54 in the newborn. The corticosteroids used include dexamethasone and hydrocortisone.
Prevention. Kopelman 52 assigned 70 infants less than 28 weeks to receive dexamethasone (0.2) or placebo 2 h following delivery. They chose a mean BP value of 30 mm Hg or above as normal and treated anybody with a value less than this with albumin and then dopamine or dobutamine. The mean BP was higher in the dexamethasone treated group from day 1 to day 5. However, the use of pressor agents was no different between the treated group and the placebo group. A second randomized trial examined the prophylactic administration of hydrocortisone in extremely low birth weight (ELBW) infants. 53 A total of 34 patients were randomized to receive hydrocortisone at 1 mg/kg for 2 days, then a reduced dose of 0.3 mg/kg every 12 h for a further 3 days; or placebo. They chose absolute BP values of <24 mm Hg for <750 g or <25 mm Hg for <1000 g and found that those who received hydrocortisone needed less inotropic support. No data is provided on clinically important outcomes. Two patients in the hydrocortisone group required insulin infusions and one had a gastric perforation.
Treatment.
A number of studies have investigated the use of corticosteroids in established hypotension. Gaisssmaier et al. 39 compared dexamethasone versus placebo in hypotensive infants who were starting on an epinephrine infusion. Dexamethasone was administered concurrently with epinephrine infusion. They found that in all 17 infants, there was a significant increase in BP 4 h following infusion, and that the duration of epinephrine use was significantly shorter in the steroid treated group. Two studies published in abstract form were identified which compared hydrocortisone versus placebo. The first 54 randomized 26 hypotensive low birth weight neonates (all of whom were on dopamine at 20 mcg/kg/min) to receive 5 mg/kg/day of hydrocortisone in four doses and found that those who received hydrocortisone had a more rapid increase in mean BP, but that those who received placebo also had a sustained increase in BP. There was no difference in the incidence of IVH. The second study 55 randomized 24 neonates less than 1250 g who were hypotensive in the first day of life to receive hydrocortisone 20 mg/kg/day in four doses over a 24 h period or placebo. There was a statistically significant reduction in the amount of inotrope required. No difference was noted in IVH rate, and no long-term data were presented.
A more recent study 56 randomized preterm infants with a mean arterial pressure below their gestational age who had received at least 30 ml/kg of normal saline and were receiving at least 10 mg/kg/min of dopamine to 3 mg/kg/day of hydrocortisone for 5 days. The babies receiving hydrocortisone had a slightly faster increase in their BP, but no clinical differences in outcomes were shown.
In summary, corticosteroids appear to increase BP in preterm infants, a huge range of different doses have been examined. No improvement in any clinical outcomes has been demonstrated, the minimal effective dose is unknown and there are no data regarding long-term neurodevelopment.
Comparisons of two treatment modalities
There is a Cochrane review 57 comparing early volume resuscitation with dopamine use. Two small randomized unblinded studies were identified, both of which used albumin. 50, 58 The conclusion was that dopamine was more successful than albumin at correcting low BP, but that there were no data on clinically important outcomes. The study by Lundstrom, 50 it should be noted, only enrolled preterm babies with a mean arterial pressure between 29 and 40 mm Hg. Randomized infants had measurements of left ventricular output (Doppler) and cerebral blood flow (intravenous xenon clearance). BP was increased 20% by dopamine, LVO was increased by 16% and cerebral blood flow was not significantly affected. Therefore, systemic and cerebral vascular resistances were increased by dopamine, but right ventricular output was not measured, therefore the effects of either therapy on systemic perfusion are uncertain.
There is one trial which compared dopamine with hydrocortisone in hypotensive preterms. 59 There was no significant difference in the improvements in hypotension, and no clinically important differences in the short term.
Discussion

Indications for treatment
There is no BP threshold that has adequate support in the literature that adequately predicts a poor outcome in the preterm infant. Infants with low BP who are clinically well, 4 or who have adequate systemic blood flow, 60 may be predicted to do well without intervention. Although clearly some BP is required, there does not appear to be a particular threshold; an adequate BP for one infant, with low resistance, may be inadequate for another with higher resistance, for example. There is no BP threshold below which intervention to increase BP has been shown to improve outcomes. It may well be that no such simple threshold exists, and other ways to define infants who are at risk, and may benefit from intervention, need to be evaluated more widely.
Having noted the lack of a clear threshold for treatment based on BP numbers, further examination of the literature to determine if there are interventions of proven value could be considered moot. However, we reasoned that, if there were studies that showed that babies with lower BPs had less brain injury when treated, even though the eligibility was by some arbitrary criterion that by itself had limited predictive value, then that would be good evidence to support treating with that particular intervention, whatever it was. That is why even with a negative first part of the review, the remaining parts were still pursued.
Fluid boluses
Ninety-six percent of neonatologists in Canada commence treatment for hypotension with a fluid bolus. 61 However, most infants who are hypotensive are not hypovolemic, but have normal circulating blood volumes. Cohort studies performed 13 to 30 years ago by Barr, 62 Wright 63 and Bauer 64 showed no relationship between blood volume and BP, a more recent study confirms this. 65 There are many uncontrolled evaluations of the effect of volume infusion which were not eligible for our systematic review, many of which showed little or no response to volume administration. 62 It is a common observation that infants receiving a volume bolus have little change in the BP, and any changes which may be noted are transient. In one short-term physiologic study reported as an abstract, a bolus of 10 ml/kg of 5% albumin, administered to hypotensive preterm neonates, increased BP by 2.7 mm Hg and left ventricular output by about 20% but did not affect right ventricular output. 66 In other words, ductal shunting increased, but there was no effect on systemic blood flow. This study reinforces the importance of measuring both left and right ventricular output in preterm infants during hemodynamic studies. A similar uncontrolled study 67 of the effects of 20 ml/kg of a 10% albumin solution showed a small effect on BP (mean elevation of 4 mm Hg). That study documented increases in left ventricular output, but right ventricular output was not measured, left atrial and ventricular distension (but not right sided) occurred after the bolus, also suggesting that ductal shunting was significantly increased. In contrast, the study by Osborn 42 measured SVC flow and right ventricular output in infants with low blood flow, who were not necessarily hypotensive (mean arterial pressure 26 in one group and 30 in the other) immediately after giving a saline bolus. They did show a 22% increase in right ventricular output, suggesting that short-term increases in perfusion may occur in infants with low systemic blood flow. The infants were all immediately started on an inotrope, so the duration of the effect is unclear.
There are a number of potential adverse effects of volume resuscitation including pulmonary, cardiovascular and central nervous system complications. The volume of fluid administered during the first few days of life in the preterm correlates well with subsequent development of bronchopulmonary dysplasia (BPD). 68 This correlation has been confirmed by a prospective controlled trial which demonstrated improved survival and decreased BPD rates in preterm that were randomized to low fluid intakes versus those given a more liberal fluid intake. 69 Goldberg 70 found an increase in the incidence of IVH in preterm infants receiving rapid volume expansion. Greenough 71 reported adverse neurological outcomes in patients who had received colloid infusion. Multiple fluid boluses are associated with increased mortality in the preterm infant. 72 The amount of sodium contained in a single fluid bolus is within the range shown in two randomized trials to increase BPD. 73, 74 Recent reviews 75 continue to recommend administering 10 ml/kg of normal saline slowly and documenting the response for all infants with a low BP. However, the routine use of fluid boluses in hypotensive preterm babies in the first days of life is not supported by any empirical data, has no physiologic basis and is associated with worse outcomes. In view of the lack of any evidence of benefit and the existence of cohort and case control study evidence of harm, it is a practice that should be avoided outside of a randomized clinical trial, unless there is clinical evidence of volume depletion.
Inotropes
All of the commonly used pressor/inotrope agents are catecholamines with varying affinity for multiple different receptors, and complex cardiovascular responses. The principal action of dopamine in the preterm infant is as a vasoconstrictor that may lead to a decrease in systemic blood flow. Dobutamine increases blood flows, but does not reliably increase BP; it may be a good choice for cardiovascular support to improve perfusion, but not as a treatment for hypotension (which may not need to be treated!) Epinephrine has been studied very little and the cardiovascular effects need to be better defined.
Other inotrope/vasopressors such as milrinone, a phosphodiesterase inhibitor, which has been reported to be used in only one study in preterm neonates 76 and novel agents such as levosimendan, a myofilament Ca 2 þ sensitizer, not yet studied in neonates, will require much more investigation before they can be used with confidence. Such agents may have very different effects in the newborn, and particularly in the preterm, to their effects in older subjects due to the dramatic developmental changes in cardiovascular structure and function, which occur after preterm birth.
Corticosteroids
Corticosteroids are now prescribed with increasing frequency for the management of hypotension, with almost 10% of VLBW receiving corticosteroid (predominantly hydrocortisone) for the management of hypotension in a recent prospective evaluation of post-natal steroid use. 77 This trend is worrying considering the potential short-term adverse effects and the lack of any data on long-term follow up. There are a number of retrospective case series documenting cardiovascular responses to both dexamethasone 78 therapy and hydrocortisone 79 therapy. Fauser 78 noted that the mean BP in a cohort of 22 ELBW infants increased significantly up to 8 h post-dose, and of 10 babies who had severe hypotension, 8 had their epinephrine infusion stopped after 8 h. Seri 79 noted, in a review of 21 patients who were hypotensive and receiving inotrope support, that mean BP increased significantly following hydrocortisone therapy at 2 to 6 mg/kg/day. There was no control group for either of these studies. The results of our systematic review confirm that steroids, not surprisingly, appear to elevate BP. But there is no evidence that clinical outcomes are improved. The use of corticosteroids for prevention or treatment of hypotension cannot be recommended unless prospective randomized-controlled trials demonstrate that clinical outcomes are improved.
Conclusions
This critical and systematic review reveals that there is very little evidence to support the commonest current approaches to the management of hypotension in the newborn. There is insufficient evidence to define an acceptable BP. There is no evidence to suggest that intervention is associated with any improved long-term outcome; indeed it is possible that the contrary may be true; intervention is statistically associated with adverse outcomes. 32, 80, 81 It is clear that some babies have poor peripheral oxygen delivery, and may require, and hopefully benefit from, intervention. These babies cannot, from this systematic review, be defined by any particular BP threshold. How best to diagnose these shock states and intervene will require further study. Physiologic studies of infants with shunts should measure systemic perfusion (right ventricular output or SVC flow) and not just left ventricular output.
This lack of supportive information regarding the use of therapies to increase BP, all of which are potentially toxic, 82, 83 is a major concern. 84 In some NICUs, as many as 98% of the extremely low gestational age babies are exposed to these therapies. 5 The entire paradigm of treating babies solely on the basis of a low mean arterial pressure should be revisited. A combination of low BP with clinical signs of poor perfusion appears to be more strongly correlated with poor outcomes. 4 A low systemic blood flow is also strongly associated with poor clinical outcomes, in particular the late occurrence (between 12 and 48 h of age) of a P/IVH 60 and of poor long-term neurodevelopment. 85 Treating infants with either of these two criteria, which probably overlap, must be prospectively examined to determine whether outcomes are improved.
It is time for this issue to be resolved in the form of prospective clinical trials of cardiovascular support in the newborn, including different intervention criteria, and different modes of intervention, to determine whether we can improve short-and long-term clinical outcomes in this particularly vulnerable group of patients.
